Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives
Pharmaceuticals · 22.07.2025 · 18 (8) · 1083
DOI: 10.3390/ph18081083 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 22.07.2025. Verfasst von Yeongbeom Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Smart Health Science and Technology, Kangwon National University, Chuncheon 24341, Republic of Korea. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Heat shock protein 90 (HSP90) is a molecular chaperone that plays a pivotal role in the stabilization and functional activation of numerous oncoproteins and signaling molecules essential for cancer cell survival and proliferation. Despite the extensive development and clinical evaluation of HSP90 inhibitors, their therapeutic potential as monotherapies has been limited by suboptimal efficacy, dose-limiting toxicity, and the emergence of drug resistance. Recent studies have demonstrated that combination therapies involving HSP90 inhibitors and other anticancer agents such as chemotherapeutics, targeted therapies, and immune checkpoint inhibitors can enhance anticancer activity, overcome resistance mechanisms, and modulate the tumor microenvironment. These synergistic effects are mediated by the concurrent degradation of client proteins, the disruption of signaling pathways, and the enhancement of antitumor immunity. However, the successful clinical implementation of such combination strategies requires the careful optimization of dosage, administration schedules, toxicity management, and patient selection based on predictive biomarkers. In this review, we provide a comprehensive overview of the mechanistic rationale, preclinical and clinical evidence, and therapeutic challenges associated with HSP90 inhibitor-based combination therapies. We also discuss future directions leveraging emerging technologies including multi-omics profiling, artificial intelligence, and nanoparticle-mediated delivery for the development of personalized and effective combination regimens in oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Smart Health Science and Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.
- Department of Biotechnology and Bioengineering, College of ACE, Kangwon National University, Chuncheon 24341, Republic of Korea.
- Institute of Fermentation of Brewing, Kangwon National University, Chuncheon 24341, Republic of Korea.
- Department of Environmental Engineering, College of ACE, Kangwon National University, Chuncheon 24341, Republic of Korea.
- Department of Biomedical Engineering, College of Engineering, University of North Texas, Denton, TX 76203-5017, USA.
ORCID-Profile: Hyun-Ouk Kim, Suk-Jin Ha, Jeong-Ann Park, Kwang Suk Lim
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, Y., Lim, S. Y., Kim, H. O., Ha, S. J., Park, J. A., Won, Y. W., Chae, S., & Lim, K. S. (2025). Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives. Pharmaceuticals, 18(8), 1083. https://doi.org/10.3390/ph18081083
Vancouver
Kim Y, Lim SY, Kim HO, Ha SJ, Park JA, Won YW, et al. Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives. Pharmaceuticals. 2025;18(8):1083. doi:10.3390/ph18081083
BibTeX
@article{Kim2025,
author = {Kim, Yeongbeom and Lim, Su Yeon and Kim, Hyun-Ouk and Ha, Suk-Jin and Park, Jeong-Ann and Won, Young-Wook and Chae, Sehyun and Lim, Kwang Suk},
title = {Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {8},
pages = {1083},
doi = {10.3390/ph18081083}
}
EUVIMED